Cargando…
Effectiveness of omalizumab in children and adolescents with uncontrolled allergic asthma: a case series from Poland
INTRODUCTION: Omalizumab has been successfully used as a supplementary therapy to improve asthma control in children aged ≥ 6 years with moderate or severe persistent allergic asthma. AIM: To evaluate effectiveness ofomalizumab in children and adolescents with uncontrolled allergic asthma. MATERIAL...
Autores principales: | Sztafińska, Anna, Gwardys, Mikołaj, Podlecka, Daniela, Mospinek, Ewa, Stelmach, Iwona |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330849/ https://www.ncbi.nlm.nih.gov/pubmed/34377123 http://dx.doi.org/10.5114/ada.2021.107929 |
Ejemplares similares
-
Omalizumab as a new therapeutic approach for children with severe asthma
por: Jerzyńska, Joanna, et al.
Publicado: (2014) -
Children with severe asthma can start allergen immunotherapy after controlling asthma with omalizumab: a case series from Poland
por: Stelmach, Iwona, et al.
Publicado: (2015) -
Quality of life in asthmatic children and their caregivers after two-year treatment with omalizumab, a real-life study
por: Sztafińska, Anna, et al.
Publicado: (2017) -
Omalizumab in the prevention of anaphylaxis during immunotherapy: a case report
por: Stelmach, Iwona, et al.
Publicado: (2014) -
Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US
por: Zafari, Zafar, et al.
Publicado: (2018)